Credit: PROFESSOR JOHN ZAJICEK/Science Source
And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.
The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.
Walk with us.
The Food and Drug Administration has approved once-daily oral ponesimod (Ponvory, Janssen) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Results from a pivotal phase 3 clinical trial show the drug was associated with nearly a third fewer annual relapses, compared with the MS drug teriflunomide.
A range of physical therapy interventions – particularly pelvic floor muscle training and mindfulness training – can help alleviate sexual dysfunction in people with multiple sclerosis (MS), according to a new study.
Autologous hematopoietic stem cell transplant (AHSCT) shows promise for the treatment of relapsing multiple sclerosis (MS), but prospective clinical trials need to be done to confirm findings. The treatment could best be applied to patients aged under 50 years with disease duration less than 10 years, who are ineligible for disease-modifying therapies, or who have breakthrough symptoms with these treatments, such as clinical relapses or new inflammatory central nervous system lesions.
Gray-matter atrophy was found in almost all the brain networks of patients with multiple sclerosis (MS), yet varies across phenotypes, a multicenter European study has confirmed, with atrophy in certain areas predicting disability and clinical worsening.
Researchers have developed a new classification of cognitive function for patients with multiple sclerosis (MS) that is based on the identification of five cognitive phenotypes.